Skip to content
NYSE · INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL · LARGE CAP

Danaher Corp. DHR

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$24.6B
▲ 2.9% YoY
$3.6B
▼ 7.3% YoY
$5.3B
▼ 0.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Danaher operates through three segments—Biotechnology, Life Sciences and Diagnostics—comprising more than 15 operating companies with leadership positions in the biotechnology, life sciences and diagnostics sectors. As of December 31, 2025, the Company had approximately 60,000 employees. The Company's research and development, manufacturing, sales, distribution, service and administrative facilities are located in approximately 50 countries. The Biotechnology segment offers equipment, consumables, software and services used to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers instruments, consumables, services and software used to study the basic building blocks of life, including DNA, RNA, proteins, metabolites and cells, and to identify new therapies and test and manufacture new drugs, vaccines and gene editing technologies. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. Danaher originated in the early 1980s, when Steven M. and Mitchell P. Rales, who became the Company's founders, began building the business that grew into Danaher.

Written from the business description in DANAHER CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.

Growth

USD 24.6B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 24.6 · Net income 3.6
10B20B
2007201020132016201920222025
Compound annual growth
−2.7%
+2.0%
+5.5%
+4.6%
−20.6%
−0.2%
+0.7%
+4.8%
−19.4%
+0.6%
+0.6%
+4.4%
+67.0%
+44.0%
+26.8%
+33.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.0% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

15 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 19.1% · Net 14.7%
10%20%
200720162025
ROE
FY2025 · ROE 7.1%
5%10%15%
200720162025
Three returns, three denominators.

Each USD of equity produced 7 cents of profit this year.

Cash & shareholders

USD 3.8B
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 5.3
3B6B
200720162025
Net buybacks $B Dividends $B
FY2025 · Dividends 0.9 · Net buybacks 2.9
2.5B5.0B-0.5B-1.0BDividendsNet buybacks
2007201020132016201920222025

USD 878.0M in dividends and USD 2.9B in buybacks — 105% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 83.5B
EquityUSD 52.5B
CashUSD 4.6B
Gross debtUSD 18.4B
Net debtUSD 13.8B
Current ratio1.87×

Net debt stands at 26% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
DHR, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B24.623.923.926.624.822.317.917.015.516.914.412.918.318.316.112.610.512.711.0
Operating income $B4.74.95.27.56.44.23.33.12.62.72.22.03.13.22.62.01.41.91.7
EBITDA $B5.45.65.98.28.46.04.54.23.73.93.02.84.04.03.32.41.82.21.9
Income tax $B0.60.70.80.81.10.80.90.60.40.50.30.40.80.70.50.50.20.40.4
Net income $B3.63.94.87.26.43.63.02.72.52.63.42.62.72.42.21.81.21.31.4
Free cash flow $B5.35.35.87.47.15.43.33.42.92.93.33.33.03.02.31.91.61.71.5
EPS, diluted $5.055.296.389.668.614.894.053.743.533.654.743.633.803.363.112.641.731.984.19
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %242017111217181615161192433433
ROE %7.17.69.215.115.110.410.39.710.110.914.311.413.013.314.214.210.713.4◌
Shares out B0.710.720.740.730.710.710.700.700.700.690.690.700.700.690.690.660.320.32◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 92 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityIndustrial Instruments For Measurement, Display, and Control
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image